Background

Drug Discovery in the Present Era
Whereas drug discovery of the past was driven by communications between biologists and chemists, today it relies on combinatorial chemistry and automated high-throughput screening (HTS), testing large numbers of potential drug candidates against equally large numbers of hypothetical therapeutic targets (Drews, 2000) . This modern strategy has been criticized (Ulrich and Friend, 2002 and Wood, 2006) . Recent estimates of the attrition rate of drug compounds entering phase I clinical trials exceed 90% (Ganter et al., 2005) and the FDA (2004) has officially documented an industry-wide pipeline problem.
Fortunately, the advent of high-throughput drug screening technologies has coincided with the introduction of high-throughput genomic technologies that promise to produce biological knowledge on pace with the increasing number of drug candidates. In particular, gene expression microarrays facilitate the simultaneous expression measurement of thousands of genes, enabling a genome-wide search for differentially expressed genes due to pharmaceutical intervention. The set of differentially expressed genes associated with a drug compound, sometimes called the "gene expression fingerprint," is arguably representative of the global biological effect, i.e., efficacy, toxicity and all side effects (Ulrich and Friend, 2002) , and may provide insight into long-term health effects using short-term studies (Orphanides, 2003) .
The Search for Differentially Expressed Genes
Finding the differentially expressed genes in a microarray experiment is a difficult task encompassing statistical multiple testing problems. In particular, the problem requires the simultaneous testing of the following hypotheses: H 0i : gene i is not differentially expressed w.r.t. treatment, H 1i : gene i is differentially expressed w.r.t. treatment, for i = 1, . . . , N, where N is typically in the thousands.
In frequentist literature, multiple testing adjustments are often made to p-values or test statistics in order to maintain control of a generalized Type I error. Control of the false discovery rate (FDR) is particularly common in microarray literature, as substantial increases in power are achieved when one is willing to tolerate a small number of false discoveries relative to total discoveries (Dudoit et al., 2002) . The well-known procedure of Benjamini and Hochberg (1995) maintains FDR control for independent test statistics as well as other specific dependence structures (Benjamini and Yekutieli, 2001) , and serves as a reference methodology for comparisons in this paper. Refer to Dudoit et al. (2002) for a thorough exposition of multiple testing in the context of microarray experiments.
Multiple testing methods based on posterior probabilities of differential expression tend to appear in the literature as "Bayesian" or "empirical Bayes" methodologies, though these techniques often employ frequentist estimation. The posterior probabilities of differential expression can be used to provide model-based control of the FDR in the direct posterior probability approach described in Newton et al. (2004) . For interesting and relevant applications of Bayesian multiple testing to microarray experiments, see Efron et al. (2001) , Do et al. (2005) , Newton et al. (2004) , and Lewin et al. (2006) .
The Impact of Animal Microarray Data
The FDA's (2004) analysis of the pharmaceutical pipeline problem noted a lack of animal toxicological models and estimated that hundreds of millions of dollars could be saved by enhancing preclinical prediction of drug failures. Though human toxicological prediction from animal experiments is limited and dependent upon the particular animal and biological system (Greaves et al., 2004) , animal microarray technology represents a relatively unexplored tool. Debouck and Goodfellow (1999) argue that gene expression profiling in animal model systems is "critical" to future drug discovery and validation efforts, but warn that interpretation of preclinical microarray data is especially difficult, as a single amino acid difference between animal and human proteins can differentiate whether a particular drug compound has an effect.
The obvious fact that animals and humans have different genes would seem to limit the use of preclinical gene expression data to well-understood model systems. Assistance arises, however, from the field of comparative and evolutionary genomics, where there has been recent interest in the evolutionary relationship known as "orthology" (Sonnhammer and Koonin, 2002) . According to Sonnhammer and Koonin, the descriptor "orthologs" is often misused to mean genes in different organisms that have the same function, whereas a more correct definition is "two genes from two different species that derive from a single gene in the last common ancestor of the species." Regardless, orthology arguments abound for a variety of genes and species. In particular, the Mouse Genome Informatics (MGI) group warehouses a continuously updated database of thousands of hypothesized human and mouse orthologs (www.informatics.jax.org), with annotations of supporting evidence for each gene pair. The MGI orthologs are in fact 1:1 mappings of mouse genes to human genes, since the current database does not support known gene duplications or sets of paralogs (as explained by The Jackson Laboratory's Dr. Judith Blake via e-mail). For recent research exploiting hypothetical orthologies in the context of gene expression, refer to Kaski et al. (2005) , Jiménez et al. (2002) and Adjaye et al. (2004) .
GlaxoSmithKline's Integrative Biology Initiative
In 2000, GlaxoSmithKline launched the Integrative Biology Initiative, an ambitious undertaking that involved the collection and warehousing of highthroughput bioinformatic data from multiple platforms, with the goal of understanding mechanisms of human disease and treatment. In addition to human data, the Integrative Biology Initiative included an equally rigorous preclinical component designed to investigate novel applications of animal data to human target validation and biomarker discovery.
Type-II Diabetes Mellitus was the first disease project undertaken by Integrative Biology, where both preclinical and clinical experiments were carried out to investigate the treatment rosiglitazone. The preclinical experiment included C57BL/6J laboratory mice fed a high fat diet such that they developed symptoms consistent with Type-II Diabetes Mellitus; the clinical experiment included only human subjects naturally suffering from the condition. Gene expression data was collected from subcutaneous fat cells of both mouse and human subjects using the Affymetrix corporation's GeneChip R oligonucleotide microarrays (the Human Genome U133 Plus 2.0 Array and the Mouse Genome MOE430A Array). Preprocessing and probe set summaries were computed using Affymetrix MAS 5.0 software, and some data cleaning was done by GlaxoSmithKline statisticians. Additional data preprocessing steps, including the summarization of probe set measurements to the gene level and the omission of certain data, are described in Section 4.4.
Description of the GlaxoSmithKline Data
For the clinical experiment, data are available for 24 humans; 13 were given the treatment rosiglitazone and 11 were given a placebo. Every human had gene expression measurements collected at two time points, one before the experimental intervention and one at the study's completion (eight weeks later). Two descriptive covariates were collected: prior therapy status (with four categorical levels) and concomitant medication status (with two categorical levels). The U133 Plus 2.0 Array provided usable expression measurements for 20,090 human genes.
For the preclinical experiment, data are available for 19 mice; 9 were given the treatment rosiglitazone and 10 were given a placebo. Gene expression measurements are collected at the end of the study, and the MOE430A Array provides usable expression measurements for 11,398 genes.
As of November 3, 2007, the MGI database listed 16,928 pairs of mouse and human genes hypothesized to be orthologous, based on various evidence criterion. The intersection of the GlaxoSmithKline data set with the MGI orthologs yielded 9,683 purported orthologs augmented with mouse and human gene expression data.
Joint Multilevel Modeling
Linear Models for Gene Expression Data
From the GlaxoSmithKline/MGI data set, let y Mij and y Hik denote gene expression measurements from the i th MGI gene pair for the j th mouse and k th human. The following linear models parsimoniously describe the data: (Affymetrix, 2001 citing Speed, 2000 , we choose to directly model the raw expression data in light of contextually problematic features of the log-transformation, discussed in Chudin et al. (2001) and Durbin et al. (2002) . For the i th mouse and human gene, α Mi and α Hi are baseline expression levels and σ Mi and σ Hi describe among subject expression variability. The human parameter vector γ T i describes the linear relationship of the covariates to the mean expression, and is included in the model to account for otherwise unexplained variability. Most importantly, β Mi and β Hi describe the differential expression of the respective mouse and human genes due to a treatment intervention. Thus, the multiple hypotheses described in Section 1.2 can be reformed as
for the i = 1, . . . , 9683 human genes, and
for the i = 1, . . . , 9683 mouse genes.
Though perhaps β Mi and β Hi are best thought of as fixed, unknown quantities, there are compelling reasons to adopt a random modeling framework. The key is to model (β Mi , β Hi ) so that something is gained by the pooling of human and animal gene expression data, and probabilistic models provide two helpful tools: (i) correlation, and (ii) mixture distributions to deal with hypothetical subgroups of genes.
The I-Ortholog Hypothesis
The MGI gene pairs focused on in this research (Section 1.3) are purported orthologs hypothesized to have been conserved from a single gene in a common ancestor. While Sonnhammer and Koonin (2002) clarify that orthology is not equivalent to functional similarity, such evolutionary conservation suggests that orthologs serve similar (and important) purposes in their respective organisms. In a search for mouse genes that are predictive of their human counterparts, the MGI orthologs are a logical place to start.
As this research is concerned with finding differentially expressed human genes, some additional machinery is necessary to incorporate the mouse data. We define a new class of mouse and human gene pairs, herein called I-Orthologs. A mouse and human gene pair is an I-Ortholog if the response of the mouse gene to an arbitrary treatment intervention is informative about the response of the human gene to the same stimulus, and vice versa. We assume that the set of I-Orthologs is non-empty, though anticipate that only a subset of the MGI orthologs are in fact I-Orthologs. Among thousands of orthology hypotheses, some may be incorrect and others may not be useful for species extrapolation.
In the definition of I-Ortholog, that a mouse gene is "informative" of human response is left intentionally vague, as we wish to separate the I-Orthology concept from future models of the concept. Here, for concreteness, we focus on the GlaxoSmithKline data set and the differential expression parameters β Mi and β Hi . If a gene pair is an I-Ortholog, then intuitively (β Mi , β Hi ) would either lie in the first quadrant (the treatment increases the expression of both mouse and human genes), the third quadrant (the treatment decreases the expression of both mouse and human genes), or the origin (the treatment had no effect on either gene). In yet a greater leap, we hypothesize a population mean model for the I-Orthologs,
as illustrated in Figure 1 . Model (3) specifies that the latent differential expression coefficients β Mi and β Hi covary about a line passing through the origin. In other words, there is a common multiplier relating differential expression of an animal ortholog to its human counterpart. If this construction proves useful in practice and generalizes to a larger population of potential human treatments, then the animal genes comprising the I-Orthologs will likely serve as useful predictors of human differential expression in future preclinical testing applications.
Latent Modeling
In this section we develop a latent bivariate model for the differential expression vector (β Mi , β Hi ) T , i = 1, . . . , 9683, from the GlaxoSmithKline/MGI data set and models (1) and (2). Consider the following latent binary variables:
• A Hi = 1 (0) if treatment did (did not) affect gene i among humans. Section 2.3.1 discusses the model-based framework used in this research, and Section 2.3.2 introduces a latent model for (β Mi , β Hi )
T .
Latent Model Assumptions
We define the probability that an arbitrary gene pair in the MGI database is an I-Ortholog as
Assuming similar pharmaceutical interventions in humans and mice differentially express the same proportion of genes on average, we furthermore define
allowing for a useful reduction of parameters and a pooled estimate of η. Additionally, we assume
where ⊥ is the independence relation. Assumption (6) states that treatment indiscriminately affects I-Orthologs and non-I-Orthologs alike. From Assumption (7), it follows that for non-I-Orthologs, mouse differential expression status is uninformative of human differential expression status, and vice versa. Assumption (8), from which Pr(A Hi = 0|A Mi = 0, O i = 1) = 1 can be derived, essentially says that I-Ortholog gene pairs always agree with respect to differential expression. The distribution of (O i , A Mi , A Hi ) completely follows from (4)-(8), as
where the second equality follows from (4) and (7) and the last equality follows from (6). Noting that Pr(A Mi = j|A Hi = k, O i = 1) takes only the values 0 or 1 according to (8),
where the first equality follows from (4) and (7).
Conditional on a treatment effect having occurred for the i th mouse or human gene, we model the latent differential expression with the normal distribution, largely for convenience:
In the literature, Blangiardo et al. (2005) and Lewin et al. (2006) also model differential expression parameters with the normal distribution, though in both cases the gene expression data are log-transformed. The non-differentially expressed genes are assumed to have differential expression parameters of zero, modeled with degenerate distributions:
Also in the literature, Efron et al. (2001) and Newton et al. (2004) model non-differentially expressed genes in similar manner. For differentially expressed non-I-Ortholog gene pairs, we assume
and thus (β Mi , β Hi )|O i = 0 can be represented as a bivariate normal with zero correlation. For differentially expressed I-Orthologs, a bivariate normal distribution with correlation ρ is used:
Note that (14) is actually a generalization of I-Ortholog model (3) discussed in Section 2.2, as E(β Hi |β Mi ) is not forced to pass through the origin. Though the parameter constraint μ H − ρσ H /σ M = 0 would accomplish this, no such constraints are applied in this paper.
Finally, this research operates under the working independence assumption,
Though genes are known to interact and the change in expression of one gene may affect another (Stuart et al., 2003) , it is generally not practical to take gene dependence structure into account when modeling expression. For instance, Newton et al. (2004) note that their presented methodology "deals only with the two-group comparison and [ignores] dependence among genes." Do et al. (2005) state that the independence approximation is "still useful to determine whether expression level differences are significant solely on a gene-by-gene basis." 
A Latent Model for Joint Differential Expression
There are a few notable properties of distributional model (16), including the absence of a density on the real plane due to the degenerate component N(0, 0). 
A Model for Estimated Treatment Effects
The latent quantities β Mi and β Hi are unobserved, but lie at the bottom of a hierarchical model with estimable parameters. We observe gene expression data for mice and humans that, by hypothesis, follow linear models (1) and (2). Least squares estimation with mouse and human data sets in isolation yields estimatesβ Mi andβ Hi , with the familiar property 
. ( > 0, the distribution of (β Mi ,β Hi ) has a density on R 2 :
where 
with densities
where g(z; μ Z , σ 2 Z ) is the univariate normal density with argument z, mean μ Z and variance σ 2 Z . Relaxing assumption (5), we may refer to η in (20) and (21) as η M and η H , respectively. Note that θ and ρ do not appear in (20)- (23), as these parameters only have relevance to the joint modeling ofβ Mi andβ Hi .
Distribution of Binary Latent Variables
The primary and secondary interests of this research are (i) the animal-assisted search for differentially expressed human genes and (ii) the identification of useful animal genes for predicting human differential expression. Thus the probabilities 
Mi ,β Hi (x, y), and (24) Pr
For comparative purposes, we are also interested in the conditional probability
where g(z; μ Z , σ 2 Z ) denotes the univariate normal density as in Section 2.4. The functions (24)-(25) are known modulo parameters that can be estimated from the data, the topic of Section 2.6.
Estimation
In Section 2.4, model (16) provides the bivariate mixture density
From N gene pairs, we construct the composite log likelihood
as in Lindsay (1988) . Composite log likelihoods are composed of true log likelihoods from marginal or conditional events, a property Lindsay exploits to demonstrate the consistency of resulting estimators. Since dependence is likely to exist among genes (Section 2.3.1), information matrix standard errors should be treated as approximate.
Even with the flexibility of composite likelihood methods, maximization of (27) is not computationally feasible given the dimensionality resulting from the gene level parameters σ 1i and σ 2i , i = 1, . . . , N. Consequently, we employ the pseudo-maximum likelihood estimation technique of Gong and Samaniego (1981) , replacing σ 1i and σ 2i in (27) with the least squares estimatesσ 1i and σ 2i . Finally, we obtain estimates of
Gong and Samaniego report that pseudo-maximum likelihood techniques produce consistent, though possibly less efficient, estimates under "fairly standard" regularity conditions. A set of 16 moment-based starting values for
For maximizing (28), the quasi-Newton algorithm (QUANEW) in SAS 9.1.3 (available in Proc NLP) worked well in practice. Despite the popularity of the EM algorithm for fitting mixture models, Redner and Walker (1984) warn that an "exorbitantly large" number of EM iterations may be necessary for a poorly separated mixture, and Titterington et al. (1985) acknowledge that Newton-based updating schemes are legitimate competitors. A custom EM algorithm for the maximization of (28) is developed in Ogorek (2008) , but the speed of QUANEW over the EM algorithm (often over 100 times faster, as implemented) led to its use in the simulations described in Section 3.
For the GlaxoSmithKline data and the 16 starting values described in Section A.3.2, the EM algorithm reached a consistent maximum which the QUANEW algorithm attained in six cases (otherwise falling short). When the QUANEW algorithm was initiated at the consistent EM maximum, there was negligible change in the resulting parameter estimates. Despite the agreement of the two algorithms in establishing a single likelihood maximum over the ensemble of starting values, we recommend taking the time to implement both algorithms in real data applications.
Decision Rules for Active Genes and Orthologs
Following the parameter estimation described in Section 2.6, and referring to the conditional distributions of A Hi and O i given the data (Section 2.5), 
and substituting estimates for unknown parameters,
The interpretation is thatp i is the estimated probability that human gene i is differentially expressed, andq i is the estimated probability that gene pair i is an I-Ortholog, given the mouse and human gene expression data (i = 1, . . . , N).
Here we apply the direct posterior probability approach of Newton et al. (2004) , where it is possible to make decisions regarding the hypotheses
which approximately control the FDR at α. Define
For approximate model-based control of the FDR at level α,
for all genes with (1 −q i ) < κ O .
Simulation
Four Simulation Experiments
Ogorek (2008) carried out exploratory simulation studies regarding the "joint" model (18), both to investigate the sampling properties ofμ M ,μ H ,σ M ,σ H , ρ,η,θ, and to assess power and Type I error control in the animal assisted search for differentially expressed human genes and I-Orthologs (Section 2.2).
To guard against overly optimistic simulation results, the simulation data were designed to resemble the GlaxoSmithKline (GSK) data in as many ways as possible. The following is a summary of the key steps implemented to ensure a proper resemblance.
1. The estimated error standard deviationsσ Mi andσ Hi from linear models (1) and (2) 3. The human covariates z ik from (2) were randomly selected with replacement from actual covariate values in the GSK data set.
4. The human covariate parameters γ 1i , . . . , γ 5i from (2) were set to constants defined by σ
−2
Hi weighted means ofγ 1i , . . . ,γ 5i .
An unfortunate consequence of the meticulous attention to detail is that problems plaguing the analysis of the GSK data were largely inherited by the simulation. In both GSK and simulation data sets, error variabilities were often large and proportional to treatment effect intensities, and signal-to-noise ratios for human genes were generally smaller than for mouse genes. Thus the simulation does not demonstrate the performance of the proposed methodology in the best possible light, rather it illuminates hypothetical performance of the methodology in situations similar to the GlaxoSmithKline data whereby parameter values and sample sizes are modulated. As discussed in Section 4.4, future enhancements in biological knowledge, bioinformatic technology, and data collection strategy are well poised to increase the utility of our dualspecies methodology. Four separate simulation experiments were conducted. The Infinite Sample Size Experiment (ISSE) involved data generated directly from the latent model (16), representing an optimal scenario with infinite mouse and human sample sizes, where σ 1i = σ 2i = 0 and β Mi , β Hi are observed. Though not ideal from a design standpoint, the exploratory nature of this experiment led to three sequentially implemented experiments investigating model (18) in the context of finite mouse and human sample sizes. The key factor levels are presented in Table 2 . The parameters μ M , μ H , σ M , σ H , and ρ were set to -2. 71, 2.83, 55.28, 6.77, and .934 , the estimates from the GlaxoSmithKline data set (Table 13) .
Finite Sample Size Experiment I (FSSE I) investigated joint model (18) with finite, but relatively large subject sample sizes: 40 humans and either 40 or 80 mice per treatment condition. Finite Sample Size Experiment II (FSSE II) was identical to FSSE I except for relatively small subject sample sizes: 10 humans and 10 or 20 mice per treatment condition (more closely resembling the GlaxoSmithKline data). Finite Sample Size Experiment III (FSSE III) also had realistically small subject sample sizes, but unlike the other two experiments, there were fewer gene pairs and a higher proportion of I-Orthologs. FSSE III represents a potential future scenario where there exists a smaller, well-understood collection of orthologs. Approximately 500 replicates were carried out for all four experiments.
Finding Differentially Expressed Genes
This section summarizes the results from FSSEs I-III regarding use of joint model (18), marginal model (21), and the procedure of Benjamini and Hochberg (1995) to find differentially expressed human genes. Metrics for comparison include estimates of average power and FDR, herein referred to as empirical power and empirical FDR, and the results are presented in Tables 3 -8 . It is important to note that this investigation compares empirical powers and empirical FDRs of competing procedures in a simultaneous fashion, where the common link is the user-specified nominal FDR. An anonymous reviewer thoughtfully questioned whether it was "fair" to compare empirical powers without fixing theoretical (rather than nominal) FDRs. While we prefer this exploratory approach which mimics how the procedures might compare under choices made by an analyst, we acknowledge that empirical FDR and power must be jointly considered when making pairwise methodological comparisons.
FSSE I
In FSSE I, control of the nominal false discovery rate was either achieved or approximately achieved under the joint model. Meaningful reductions in empirical FDR always occurred with greater proportions of I-Orthologs (θ = .4 versus θ = .2), but there were slight increases in the empirical FDR when the mouse sample size was increased (and the human sample size held constant). There was some evidence of decreasing empirical FDR when the gene pair sample size, N, was increased: when η = .25, increases in the number of gene pairs were associated with small decreases in FDR for all eight factorial combinations (when pooled over nominal FDRs .05 and .20). For both nominal FDRs, the human marginal model (21) and the procedure of Benjamini and Hochberg (1995) were somewhat conservative.
The joint model was considerably more powerful than its competitors, even in cases where empirical FDRs of the former were less than those of the latter (which occasionally happened against the procedure of Benjamini and Hochberg at nominal FDR .20). At nominal FDR .05, joint model powers ranged from .081 to .168, compared to .051 to .083 with the marginal model and .025 to .048 with the procedure of Benjamini and Hochberg; at nominal FDR .20, these powers ranged from .171 to .438 (joint), compared to .100 to .172 (marginal) and .094 to .160 (Benjamini and Hochberg) . Only small increases in power were observed from doubling the number of mice (up to a one percentage point increase), though the associated increases were proportionally greater than the corresponding increases in FDR, except in the case of θ = .2 and η = .25. The isolated effect of doubling the number of number of mice is not 303 (marginal) . Empirical FDRs at η = .5 were roughly half their η = .25 counterparts and all fell under the controlled limit at nominal FDR .20. Increased proportions of I-Orthologs (θ = .4 versus θ = .2) were associated with substantial reductions in empirical FDR (up to eight percentage points). Despite serious lapses in FDR control, the joint model considerably outperformed its marginal counterpart, often with power increases of two to three times (especially at nominal FDR .20) and smaller or similar empirical FDRs. The estimated power increase from doubling the number of mice was more pronounced than in FSSE I, up to an increase of 5 percentage points at nominal FDR .20. I-Ortholog gene pairs were again helpful, as doubling θ from .2 to .4 uniformly increased powers (up to 7 percentage point at nominal FDR .20). Additionally, joint model empirical powers were substantially higher (nearly double) when η = .5 versus η = .25. While the Benjamini and Hochberg procedure consistently provided nominal false discovery rate control, its power to find differentially expressed human genes was weak at best: a mere 1 in 1,000 genes discovered at nominal FDR .05 and 1 in 100 at nominal FDR .20. In this optimistic scenario where 80% of gene pairs were I-Orthologs, the relative power of the joint model was impressive. The joint model, with empirical FDRs of only a fraction of the marginal model, boasted respective power increases of approximately 5 to 7 and 8 to 13 times those of the marginal model at nominal FDRs .05 and .20. At nominal FDR .20, the joint model enjoyed 41 to 60 times the empirical power of the Benjamini and Hochberg procedure and smaller empirical FDRs. Increases in the number of mice corresponded to substantially higher empirical power, the greatest being a 20 percentage point increase when η = .5 and at nominal FDR .20. Also notable at this factorial combination, 73.2% of all differentially expressed genes were discovered using the joint model. 
FSSE III
Finding I-Orthologs
This section deals with the search for I-Orthologs in Finite Sample Size Experiments I-III. The key metrics are average power and empirical FDR, and the results are presented in Tables 9 -11 . Empirical FDRs for I-Ortholog discovery often fell both above and below their nominal levels, sometimes substantially so. Powers to find I-Orthologs were typically very low. In FSSE I, the power to find I-Orthologs ranged from .01 to .41 percent at nominal FDR .05 and 0.6 to 5.4 percent at nominal FDR .20. In FSSE II, empirical detection rates spanned 8 in 10,000 to a mere 3 in 100,000 at nominal FDR .05, and 12 in 10,000 to 18 in 1,000 at nominal FDR .20. In FSSE III, with 80% of all gene pairs as I-Orthologs, the four-fold increase in the nominal FDR (.05 to .20) 
Finite Sample Size Bias
In the Finite Sample Size Experiments, bias in parameter estimation was often extensive in both the joint model (18) and the marginal models (22) and (23). The most predictable bias across experiments and factor levels was a downward bias inη, which was severe when the number of subjects was small. Such bias, if isolated, would have the effect of making procedures conservative. Thus the failures of FDR control in FSSE II, with the smallest of sample sizes, would seem to have happened in spite of this bias. However, the system is hardly one dimensional. One possible explanation for the testing mishaps of FSSE II isρ, which experienced considerable downward bias in FSSE II and only slight downward bias in FSSEs I and III. One of the driving factors behind development of the joint model was the hypothesis that indefinite improvements in human parameter estimation and testing would be achieved by isolated increases in the number of (less expensive and readily available) laboratory mice. In actuality, the extent to which this hypothesis is true depends on the situation. On one hand, estimators for μ H , σ M , θ and η tended to enjoy reductions in bias upon increasing the mouse sample size and holding the human sample size constant. On the other hand, for some parameters and experimental combinations, estimation bias actually increased under this scenario, an example beingσ H in the joint model. As for the effects of other factors, biases were generally reduced at θ = .4 versus θ = .2 (in FSSEs I-II) and η = .5 versus η = .25 (in FSSEs I-III).
It is important to note that one aspect of the simulation design (described in Section 3.1) impacted the amount of finite sample size bias in the experiments. A realization from early simulation designs was that if we were willing to ignore reality and generate β Mi and β Hi independently from σ Mi and σ Hi (from linear models (1) and (2) Before addressing this question, notice that a change in σ Mi or σ Hi can simulate at least three different possibilities. First, it can represent a change in the precision of gene expression measurement. In the future, we could expect σ Mi and σ Hi to diminish on these grounds. Second, it can represent a change in the level of homogeneity in the sample. In experiments with alike subjects or appropriate blocking, σ Mi and (especially) σ Hi would potentially be attenuated. Finally, since the "data" for our methodology consists of only (β Mi ,σ 1i ,β Hi ,σ 2i ) and σ 1i ∝ σ Mi and σ 2i ∝ σ Hi , the effect of decreasing σ Mi and σ Hi is indistinguishable from increasing the mouse and human sample sizes.
A Response Surface Study in Bias
As we question the relationship between the amount of noise and the amount of bias in parameter estimation, it quickly becomes clear that Finite Sample Size Experiments I-III are inadequate for this learning objective. Notwithstanding the fact that the subject sample sizes are never large enough to make σ 1i and σ 2i anywhere near negligible for all i = 1, . . . , N, there is also the distinct lack of a true factorial arrangement of mouse and human sample sizes. Here we remedy this situation by engaging in a response surface design meant to reveal how bias is introduced to parameter estimation during departure from the asymptotic, infinite subject sample size scenario. At the finite end of the spectrum is a scenario from FSSE II where the estimation bias was often severe: θ = .2, η = .5, with 4K gene pairs and 10 mice and 10 humans per treatment condition.
To facilitate this objective, we introduce the factors v M and v H , proportions of the full levels of variability associated with the described scenario from FSSE II. In a new simulation design, we define Representations of the seven response surface estimates are presented in Figure 3 . Note that green lines always represent the zero bias contour line (in several cases there was no space for a label). Arguably the most striking contour plot belongs toη, where even slight departures from the ISSE result in substantial downward biases. While independently decreasing either v M or v H alleviates bias, decreases in the former are more effective than in the later. Estimators of the other mixing parameter, θ, also experience downward bias as error levels depart from zero, though the relative biases are roughly half those seen inη. Furthermore, the weak-link sample size in the estimation of θ appears to be the human sample size, as decreases in v H do more to alleviate bias inθ than v M . This statement also applies to the downward-biasedρ, where the decreasing level of human variability alone is enough to reach a near-zero bias level. Estimators for σ M behave the way we predicted that all estimators would: relatively little bias that is predictably attenuated with decreases in either v M or v H . Estimators for σ H illustrate a more complex reality: decreasing v M out of proportion with v H actually increases bias. The same is basically true for estimators of μ H , but here there appears to be an optimal linear relationship between v M and v H where there is little or no bias. While it is possible that the bias relationship inμ M is similar to that ofμ H , the especially small R 2 = .029 makes its polynomial response surface difficult to interpret. 
Application
Analysis of the GlaxoSmithKline Data
From fitting models (1) and (2) to the GlaxoSmithKline mouse and human data sets (Section 1.4), the least squares estimates (β Hi ,β Mi ) and the t-statistics (β Hi /σ 2i ,β Mi /σ 1i ), i = 1, . . . , 9683, are shown in Figure 4 . Note that thê mouse t-statistics tend to be larger than those of the humans, indicating the higher signal-to-noise ratio of the preclinical experiment. In the plot of (β Hi ,β Mi ), a limited number of extreme observations receive disproportionate visual weight, and in later plots the window is altered (see Figures 5, 6 ). The joint model (18) and marginal models (20) and (21) were fit to the GlaxoSmithKline data via the estimation methodology described in Section 2.6. For all three models, estimates along with their 95% Wald confidence intervals are presented in Tables 13-14, though recall that the composite likelihood method provides only approximate standard errors and confidence intervals. Browne and Draper (2006) have furthermore warned against using Wald intervals for variance components in multilevel models.
The higher average signal-to-noise ratio in the preclinical experiment is arguably manifested inσ M , which is over eight times larger thanσ H . Sincê μ M andμ H are relatively close to zero, larger estimates of σ M or σ H indicate that β Mi or β Hi take larger values with higher probability. Thus σ M and σ H are themselves measures of signal.
The estimate of correlationρ is close to one (though the 95% confidence interval cannot rule out values as low as .7) andθ = .165, a suggestion that approximately seventeen percent of the proposed orthologs in the Mouse Genome 
074).
These genes are the most interesting as they are expected to have increased detection probabilities due to I-Orthology-based species extrapolation. While the mean and variance estimates from marginal models (20) and (21) are remarkably consistent with the joint estimates from model (18), the mixing parameter estimatesη M andη H deserve discussion. Referring to the t-statistics from Figure 4 , it is remarkable that the greater signal in the mouse data set is reflected in the estimates of σ M and σ H , rather than the inherently signal relevant η H and η M . The estimate of η H has a larger confidence interval than η M , suggesting that the former is an inferior estimate and explaining why the joint estimate of η is influenced so little by the human data.
Given the estimates from Table 13 , the estimated posterior probabilities of human differential expression,p i , and I-Orthology,q i (Section 2.5), may be computed for the MGI gene pairs, i = 1 .15, .17, .18, .78) . In fact, as the maximum probability of I-Orthology is less than .8, no I-Ortholog discoveries can be made even with a nominal false discovery rate of .20. In Figure 5 , the (β Mi ,β Hi ) and (β Mi /σ 1i ,β Hi /σ 2i ) pairs are colored red for human differential expression discoveries with .05 FDR control (p i > .886), yellow for additional discoveries with .20 FDR control (.643 ≤p i < .886) and green otherwise. While, thep i s are consistent with traditional insight based on the t-statistics (β Mi /σ 1i ,β Hi /σ 2i ), the lack of a coherent pattern in thep icoded plot of (β Mi ,β Hi ) is indicative of the wide range of variances associated with estimates of human differential expression. Often the largest values of β Hi (β Mi ) also correspond to the largest values ofσ 1i (σ 2i ), resulting in low t-statistics for differential expression.
In Figure 6 , the (β Mi ,β Hi ) and (β Mi /σ 1i ,β Hi /σ 2i ) pairs are colored red whenq i > 2θ, yellow whenθ ≤q i < 2θ, and green otherwise. The red points in the plot of (β Mi ,β Hi ), the highest observed probabilities of I-Orthology, appear to highlight the hypothesized relationship shown in Figure 1 . The yellow points, the observed probabilities which are greater than or equal to the prior estimate,θ, appear to comprise all points where mouse and human treatment effects behaved consistently at all, i.e. the points in quadrants I and III. The plot of the color-coded t-statistics has an obvious interpretation: higher values ofq i exist where there is more evidence of dual treatment effect. But there are also a few red points that do not conform to the overall pattern, indicating the impact lying on the "line" in the plot of (β Mi ,β Hi ).
Discovery and Methodology Comparisons
In this section we reflect on the differentially expressed genes found using joint model (18), human marginal model (21), and the procedure of Benjamini and Hochberg (1995 Table 15 reports the numbers of differentially expressed human genes discovered using competing methodologies. Note that the popular frequentist procedure of Benjamini and Hochberg (1995) yields far fewer discoveries 32 Statistical Applications in Genetics and Molecular Biology, Vol. 8 [2009 ], Iss. 1, Art. 2 DOI: 10.2202 /1544 -6115.1414 than the two posterior probability-based procedures. The joint model, presumably because of information obtained from the animal data, is associated with more differentially expressed gene discoveries than its marginal counterpart. Though the increase in the number of genes found from the joint model over the marginal model is modest, there are many non-ideal features of the GlaxoSmithKline data with respect to application of the joint model methodology (the topic of Section 4.4). Recall the simulation results from Section 3.2, which suggest substantial gains are possible in realistic scenarios. From Figure 7 , various agreements and disagreements between the competing procedures are apparent. Discounting number of discoveries, differentially expressed genes found by the procedure of Benjamini and Hochberg are generally found by the posterior probability-based methodologies. The joint and marginal model also agree for a vast majority of discovered genes, but both procedures are associated with sizeable numbers of genes not discovered by the other. The genes discovered by the joint model and not the marginal model are especially interesting: at nominal FDR .05 (.20), over 68% (75%) of these genes have posterior I-Ortholog probability estimates greater than the estimated prior value ofθ = .165 and over 45% (22%) have probabilities greater than twiceθ. For comparison, recall that the 75 th percentile of I-Ortholog probabilities (q i ) in the GlaxoSmithKline data is .18. We refer to the increase in differential expression probability resulting from a relatively high I-Ortholog probability as an I-Ortholog lift.
A Permutation-Based Test for the Existence of IOrthologs
The failure to find I-Orthologs in the GlaxoSmithKline data set at nominal FDRs .05 and .20 naturally casts doubt on whether the hypothesis of I-Orthology is actually supported by the data. On one hand, the estimatê θ = .165 and the 95% Wald interval of (.114, .231) suggest that there are indeed I-Orthologs in the GlaxoSmithKline data set, even if our methodology could not effectively sort them out. On the other hand, the appropriateness of Wald intervals in this maximum composite pseudolikelihood setting is highly questionable, and it is difficult to gauge the stability of estimators of θ = 0 given the location on the boundary of the parameter space. The purpose of this section is to revisit the question of I-Ortholog existence from a relatively assumption-free standpoint. Inspired by comments from an anonymous reviewer, we carried out a following permutation test for H 0 : θ = 0, described in the following steps: Before discussing the permutation distribution ofθ, it is first interesting to note that the estimates of the marginally estimable parameters μ M , μ H , σ M , σ H , and η, shown in Table 16 , were only slightly affected by the random mouse and human gene pair permutations. Since these parameters can be estimated from the mouse and human data sets independently, the invariance of the respective estimators to such permutations illustrates a desirable form of model robustness. .0000 -0.048 5%
.0000 -0.622 1%
.0000 -1.000 0%
.0000 -1.000
In Table 17 , the permutation distributions ofθ andρ, estimates which rely on the I-Orthologous relationship between mouse and human genes, are very different than their marginal counterparts. Estimates of θ are virtually 0 until the 75 th percentile. The strongly right skewed distribution reaches .046 at the 95 th percentile, and finally a maximum at .135. Withθ = .165 as a property of the MGI orthologs, we conclude there is strong evidence in the GlaxoSmithKline data supporting the existence of I-Orthologs.
The distribution ofρ under randomly permuted mouse and human gene pairs is also informative. Estimates span the entire parameter space and often settle at +1.0. Indeed, without the presence of I-Orthologs, it is impossible to obtain a meaningful estimate of ρ.
Difficulties in Modeling the GlaxoSmithKline Data
There were many challenges in applying the joint model methodology to the GlaxoSmithKline data set. The key difficulty was the signal-blurring noise of the microarray data, which often resulted in excessively large standard errors forβ Mi andβ Hi . Fortunately, microarray technology will continue to improve, knowledge regarding orthologs will expand, and future data could in principle be collected to accommodate joint model (18), all greatly enhancing the application of the proposed methodology to real data. In addition to the high levels of noise, analysis of the GlaxoSmithKline data was plagued by two particular problems: computation of gene-level expression summaries, and experimental incongruencies between the mouse and human studies. These problems are described below.
Though much research has gone into summarization of replicate probes to probe sets, no standard techniques are currently available for summarizing microarray data to the gene level (recall that ortholog hypotheses from MGI are at the gene level). In the case that there are multiple probe sets for a given gene, taking an average expression measurement is not recommended for various reasons. In at least one circumstance, described by the Affymetrix support team, two probe sets were included on a chip when only one could have theoretically worked. An anonymous reviewer introduced additional literature documenting other problems with the quality of Affymetrix probe set annotations. For instance, Perez-Iratxeta and Andrade (2005) note that Affymetrix probe set annotations to genes tend to change over time: in a two year period, some 5% of the total probe sets in the MOE 430 A/B chips experienced changes in the genes they were annotated to, and these changes greatly impacted their analysis. Additionally, Harbig et al. (2005) and Dai et al. (2005) discussed the problems stemming from poor Affymetrix gene annotations, re-identifying large proportions of probe sets using alternate bioinformatic information.
In this research, we first discarded lower-quality probe sets when those of higher quality were available for a given gene (based on an Affymetrix naming convention). If there were still multiple probe sets for the gene, the probe set with the highest treatment effect (using a regression model) was chosen to represent the gene. Any bias incurred from the nonconstant number of probe sets per gene is no worse than for the usual practice of performing analysis at the probe set level and making conclusions at the gene level. Emerging technologies such as exon arrays promise to allow gene level expression summaries, eventually rendering this problem obsolete.
There were also incongruencies between the preclinical and clinical experiments. For instance, the preclinical experiment included a "healthy" group of mice, while the clinical experiment included only humans suffering from Type II diabetes mellitus. To eliminate complication resulting from a potential disease status × treatment interaction, the decision was made to discard the healthy mouse data and keep only the data from the disease group. Another key difference between the two studies was that, while humans received only one dose level (varied to maintain glycemic control), the mice received three dose levels: 1, 3 and 10 mg/kg. The 10 mg/kg dosing level was associated with the highest signal-to-noise ratio. Greaves et al. (2004) report that single, high-dose studies in animals are often sufficient for detecting adverse events in humans, and thus the decision was made to keep only the highest dose level in the preclinical experiment (along with the control group) and to discard the lower dose levels. Genetics and Molecular Biology, Vol. 8 [2009] Reflecting on early aspirations for the dual-species gene expression model (18), this research has both validated and challenged preconceived notions. One motivating vision was quickly discarded: that model (18) is a tool enabling endless gains in human inferential power from indefinite increases of the mouse sample size. In the simulation studies described in Section 3, the increase in differential gene-finding power from doubling the number of mice was sometimes impressive (up to 20 percentage points in Finite Sample Size Experiment III), but more often the observed increases were a few percentage points or less. This metric ignores the larger enjoyed contribution of the mouse data, as removing the mice altogether typically resulted in substantial power decreases. In its most impressive scenarios, the gains from using joint model (18) versus competing procedures were remarkable. In one instance, the joint model was up to 13 times more powerful than its marginal counterpart and 60 times more powerful than the procedure of Benjamini and Hochberg (1995) , while often possessing lower empirical false discovery rates (in FSSE III, Section 3.2.3).
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When there were failures of joint model (18) or human marginal model (21) to control the false discovery rate, bias in parameter estimation was apparent. Estimators in the Infinite Sample Size Experiment (ISSE) were virtually bias-free, and the onset of bias as σ 1i and σ 2i departed from zero differed greatly among parameters. Depending on the parameter, increasing the mouse sample sizes out of proportion with the human sample size sometimes increased estimation bias. In light of the impact of bias on posterior probabilities of differential expression, new methodologies that reduce this bias, especially in small sample size settings, would presumptively lead to great enhancements in performance and practical utility.
As species extrapolation exists at the heart of this research, we reflect on the concept of I-Orthology, which comprises the machinery to make such extrapolations. The hope is that the single linear relationship specified in this research largely captures the essence of the inter-species agreement. Herein lies another opportunity for refinement of the proposed methodology: to relax the nature of the relationship between human and mouse treatment coefficients, or to allow this relationship to differ among genes. If successful, then not only could extrapolative success improve, but the current model of I-Orthology would be updated and the increased flexibility would lead to larger estimates of (a suitably redefined) θ.
Though I-Ortholog discovery in the GlaxoSmithKline data resulted in an empty set at nominal FDR .20 (the largest I-Ortholog probability was .78), the permutation methodology of Section 4.3 gives empirical weight to the I-Ortholog hypothesis. Powers to find I-Orthologs were often low in simulation studies as well, though as the simulation data were designed to resemble the less than ideal GlaxoSmithKline data (see Section 4.4), these do not necessarily reflect the ability to find I-Orthologs in future experiments. As performance in discovering I-Orthologs increased dramatically at nominal FDR .20 versus .05 in simulations, we would encourage the analyst to consider tolerating a larger proportion of false discoveries in exchange for discovering a set of likely interspecies extrapolators. In the GlaxoSmithKline data, where no discoveries were made at nominal FDR .20, including gene pairs with posterior I-Ortholog probabilities greater that half (q i > .5) resulted in 18 discoveries and a modelbased FDR estimate of .42 (with standard error .02). Additionally, we would like to suggest the possibility that a meta analysis of multiple dual-species experiments, with a variety of treatments, would facilitate I-Ortholog discovery by giving each MGI gene pair additional opportunities to demonstrate agreement or disagreement in terms of differential expression.
While the mixing parameter η essentially determines how many genes will be discovered, it does not appear to be an accurate indicator of the amount of genes that should be discovered. In the GlaxoSmithKline data set, the mouse gene expression data undeniably possessed more signal than its human counterpart (Section 4.1), however in the marginal modelsη H >η M (though it is difficult to quantify this difference due to the unreliable estimates of standard error). Instead, the amount of signal in the mouse and human data sets seemed to be embedded in the latent differential expression variability estimatesσ M andσ H . Consequently, alternative estimates for η are worth pursuing.
Even if the problem of finding differentially expressed genes was resolved, the quite independent problem of biological interpretability would remain. Whether it is presently economical to carry out the types of dual-species gene expression experiments discussed in this paper (18), this research presents a novel strategy that is potentially useful in many areas. If I-Orthology concepts fail in the context of gene expression, perhaps they will succeed in other animal-to-human biological mappings (for instance, metabolites). Regardless of how difficult the animal-to-human extrapolation problem is, or has been, emerging high-throughput bioinformatic technologies provide hope that monumental advances are near, ushering in a new era in the preclinical testing of safety and efficacy. 
A.3 Computational Issues
A.3.1 Reparameterizations
Instead of enforcing constraints on a maximization procedure, we choose to reparameterize so that numerical maximization may be carried out unconstrained. The following is a list of 1:1 transformations that used to aid in the maximization of (28) 
A.3.2 Starting Values
This section describes calculation of starting values necessary for a numerical algorithm seeking to maximize pseudo-composite likelihood (28). We assume that the least squares estimatesβ Mi andβ Hi , i = 1, . . . , N, have been calculated as well as their standard error estimatesσ 1i andσ 2i .
The starting values described in this section are guided by moment equations resulting from (18). In particular,
are useful for our purposes. 
